Patients with coronavirus disease 2019 (COVID-19) are often associated with hypercoagulability as well as some cardiovascular disease requiring antithrombotic treatment including acute coronary syndrome, atrial fibrillation, veinous thrombosis and so on. During antithrombotic therapy for patients with COVID-19, the particularity of COVID-19, effectiveness of antithrombotic therapy and interaction of special drugs should be considered. This requires individualized treatment in combination with the characteristics of COVID-19 and cardiovascular disease, the risk assessment of thrombosis and hemorrhage and the patient's own situation. On this condition, antithrombotic treatment of cardiovascular diseases may need to be adjusted on the basis of conventional treatment norms to achieve higher treatment safety and effectiveness. A safe and effective antithrombotic strategy will be of great significance to the prognosis of patients with COVID-19.